Detalhe da pesquisa
1.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol
; 186: 182-190, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38718741
2.
Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.
Br J Haematol
; 194(1): e48-e51, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34114211
3.
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.
Br J Haematol
; 186(5): e117-e121, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31090915
4.
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Cancer Discov
; 14(1): 66-75, 2024 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37930156
5.
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
Eur J Cancer
; 160: 1-11, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34801354
6.
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Int J Hematol
; 112(5): 640-649, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949374
7.
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.
J Immunother Cancer
; 8(2)2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33361337
8.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol
; 38(1): 1-10, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682550
9.
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Nat Med
; 25(6): 936-940, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171879
10.
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Nat Med
; 25(8): 1319, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31267021
11.
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Lancet Haematol
; 6(9): e448-e458, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31327689
12.
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Nat Med
; 25(6): 941-946, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171878
13.
Clinical relevance of vilazodone treatment in patients with major depressive disorder: categorical improvement in symptoms.
Prim Care Companion CNS Disord
; 16(1)2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24940525